ClinicalTrials.gg
CompletedNCT00332709Updated Nov 16, 2011Results posted

Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

A Phase 3 interventional study of Letrozole and Zoledronic acid in Osteoporosis and Postmenopausal, sponsored by Novartis. Completed at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-16.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Osteoporosis by Novartis — none open to participants now, none under way, none of them phase 3. Osteoporosis · Novartis.

Enrollment
23rd of 29
83 · median 190
Started
2006
with 6 others
Phase 3
18 of 30
none open now
Registered
13th of 30
by date

Among the 30 studies in Osteoporosis by Novartis, this one is the 23rd largest by enrollment of the 29 interventional ones that give a count, is one of 7 that started in 2006, is one of 18 in phase 3, and was the 13th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

None of the 30 studies in Osteoporosis by Novartis is open now. The open studies under Osteoporosis, anywhere →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Osteoporosis by Novartis as a file.
02

Study summary

This was a prospective, randomized, open-label, two arm phase III trial designed to evaluate the efficacy and safety of zoledronic acid in preventing bone loss in postmenopausal women with operable breast cancer who had received 4 to 6 years of adjuvant tamoxifen therapy after resection of the tumor. Patients were treated with letrozole 2.5 mg orally per day or letrozole 2.5 mg orally per day in combination with zoledronic acid 4 mg/6 months as an infusion.

This trial did not recruit patients in the United States.

03

Conditions studied

  • Osteoporosis
  • Postmenopausal

Keywords

  • Breast cancer
  • postmenopausal
  • bone mineral density
  • Zoledronic acid
  • Letrozole
  • extended adjuvant treatment.
  • Postmenopausal women with primary hormone receptor positive breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Compliant women with primary operable breast cancer after 4 to 6 years of therapy with tamoxifen (end of tamoxifen therapy within last 6 months)
  • Performance status 0-2 ()
  • Patients without severe osteoporosis at study entry
  • No evidence of relapse at the time of randomization
  • Adequate function of bone marrow, kidney, and liver

Exclusion criteria

Exclusion Criteria:

  • Estrogen- and progesterone-receptor status negative or unknown
  • Completion of tamoxifen therapy more than 6 months prior to study start
  • Inflammatory breast cancer
  • Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures.
  • Recent (within 6 weeks) or planned dental or jaw surgery
  • History of diseases with influence on bone metabolism such as Paget's disease and primary overactive parathyroid
  • Prior or concomitant therapies: chemotherapy within the last 12 months, intravenous or oral bisphosphonates, systemic , anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any drugs known to affect the skeleton (such as calcitonin, mithramycin, or gallium nitrate)
  • Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancers or in situ cancer of the cervix. Patients with previous other cancer(s) must have been disease-free for at least 5 years.
  • Patients currently receiving oral bisphosphonates must discontinue these at least 3 weeks prior to study start.

Additional protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Letrozole

    Letrozole orally 2.5 mg/day for 3 years

    Drug: Letrozole

  • Experimental
    Letrozole + Zoledronic Acid

    Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion

    Drug: Letrozole · Drug: Zoledronic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Bone Mineral Density (BMD) From Baseline to Month 36

    Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.

    Time frame: at 36 months as compared to baseline

  2. Percent Change in Bone Mineral Density (BMD) From Baseline to Month 36

    Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA) scan. ANCOVA model was used in the analysis where: Variable = Baseline, Center, Treatment BMD = (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.

    Time frame: Baseline, Month 36

  3. Change in T-score From Baseline to Month 36

    BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.

    Time frame: Baseline and Month 36

  4. Change in Z Score From Baseline to Month 36

    Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis.

    Time frame: Baseline, month 36

Secondary outcomes

  1. Change in Bone Mineral Density From Baseline to 12 Months

    Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.

    Time frame: Baseline, 12 months

  2. Number of Participants With Any Kind of Fractures, by Visit.

    Number of participants with fractures of any type since the last visit

    Time frame: Baseline, Month 6, 12, 18, 24 , 30 and 36

  3. Median Disease Free Survival (DFS)

    Disease Free Survival is measured in days and represents the number of days participants were progression free. Progression free survival is defined as the time from randomization to the date of the first documented progression or recurrence of disease or death from any cause. Median disease free survival is the time when 50% of the patients had a recurrence.

    Time frame: 36 months

  4. Change in T-Score From Baseline to Month 12

    BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.

    Time frame: Baseline, Month 12

  5. Change in Z-Score From Baseline to Month 12

    (DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis

    Time frame: Baseline, Month 12

07

Results

Posted Nov 16, 2011

Participant flow

Participant flow — Overall Study
MilestoneLetrozoleLetrozole + Zoledronic Acid
Started4041
Completed2421
Not completed1620
Withdrew: Adverse event1114
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up20
Withdrew: Administrative problems03
Withdrew: Abnormal test procedure result10

Outcome measures

PrimaryChange in Bone Mineral Density (BMD) From Baseline to Month 36

Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.

Time frame:
at 36 months as compared to baseline
Reported as:
Mean · Percent
Change in Bone Mineral Density (BMD) From Baseline to Month 36
PercentLetrozoleLetrozole + Zoledronic Acid
Change in Bone Mineral Density (BMD) From Baseline to Month 36-0.11 ± 0.140.03 ± 0.08
SecondaryChange in Bone Mineral Density From Baseline to 12 Months

Change in bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) in lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.

Time frame:
Baseline, 12 months
Reported as:
Mean · g/cm^2
Change in Bone Mineral Density From Baseline to 12 Months
g/cm^2LetrozoleLetrozole + Zoledronic Acid
Change in Bone Mineral Density From Baseline to 12 Months-0.04 ± 0.040.02 ± 0.05
SecondaryNumber of Participants With Any Kind of Fractures, by Visit.

Number of participants with fractures of any type since the last visit

Time frame:
Baseline, Month 6, 12, 18, 24 , 30 and 36
Reported as:
Number · Participants
Number of Participants With Any Kind of Fractures, by Visit.
ParticipantsLetrozoleLetrozole + Zoledronic Acid
Baseline00
Month 600
Month 1200
Month 1800
Month 2400
Month 3000
Month 3600
SecondaryMedian Disease Free Survival (DFS)

Disease Free Survival is measured in days and represents the number of days participants were progression free. Progression free survival is defined as the time from randomization to the date of the first documented progression or recurrence of disease or death from any cause. Median disease free survival is the time when 50% of the patients had a recurrence.

Time frame:
36 months
Reported as:
Median · Months

No measurements were reported for this outcome.

PrimaryPercent Change in Bone Mineral Density (BMD) From Baseline to Month 36

Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA) scan. ANCOVA model was used in the analysis where: Variable = Baseline, Center, Treatment BMD = (Month 36 BMD-Baseline BMD)/Baseline BMD\*100.

Time frame:
Baseline, Month 36
Reported as:
Mean · Percent Change in BMD
Percent Change in Bone Mineral Density (BMD) From Baseline to Month 36
Percent Change in BMDLetrozoleLetrozole + Zoledronic Acid
Percent Change in Bone Mineral Density (BMD) From Baseline to Month 36-11.34 ± 17.723.31 ± 8.32
PrimaryChange in T-score From Baseline to Month 36

BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.

Time frame:
Baseline and Month 36
Reported as:
Mean · T-Score
Change in T-score From Baseline to Month 36
T-ScoreLetrozoleLetrozole + Zoledronic Acid
Change in T-score From Baseline to Month 36-0.90 ± 1.030.46 ± 0.27
PrimaryChange in Z Score From Baseline to Month 36

Bone Mineral Density is measured by dual energy x-ray absorptiometry (DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis.

Time frame:
Baseline, month 36
Reported as:
Mean · Z-Score
Change in Z Score From Baseline to Month 36
Z-ScoreLetrozoleLetrozole + Zoledronic Acid
Change in Z Score From Baseline to Month 36-0.31 ± 0.350.25 ± 0.34
SecondaryChange in T-Score From Baseline to Month 12

BMD measured by DXA (dual energy x-ray absorptiometry) at lumbar spine, L1-L4. The T-Score is a comparison of a patient's BMD to that of a healthy 30 year of the same sex and ethnicity. The criteria of the World Health Organization are Normal is a T-Score of 1.0 or higher. Osteopenia is defined as between - 1.0 and -2.5. Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and half standard deviations below the mean of a 30 year old man/woman.

Time frame:
Baseline, Month 12
Reported as:
Mean · T-Score
Change in T-Score From Baseline to Month 12
T-ScoreLetrozoleLetrozole + Zoledronic Acid
Change in T-Score From Baseline to Month 12-0.31 ± 0.350.25 ± 0.34
SecondaryChange in Z-Score From Baseline to Month 12

(DXA). The Z-Score is the number of standard deviations a patient's BMD differs from the average BMD of their age, sex and ethnicity. A Z-score of less than minus -1.5 raises concern of factors other than aging as contributing to osteoporosis

Time frame:
Baseline, Month 12
Reported as:
Mean · Z-Score
Change in Z-Score From Baseline to Month 12
Z-ScoreLetrozoleLetrozole + Zoledronic Acid
Change in Z-Score From Baseline to Month 12-0.26 ± 0.350.37 ± 0.38

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Letrozole—6/40 (15%)35/40 (87.5%)
Letrozole + Zolendronic Acid—7/41 (17.1%)35/41 (85.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventLetrozoleLetrozole + Zolendronic Acid
VERTIGO POSITIONALEar and labyrinth disorders1/400/41
CONCOMITANT DISEASE PROGRESSIONGeneral disorders1/400/41
CHOLECYSTITISHepatobiliary disorders1/400/41
FALLInjury, poisoning and procedural complications1/400/41
LOWER LIMB FRACTUREInjury, poisoning and procedural complications1/400/41
AXILLARY MASSMusculoskeletal and connective tissue disorders1/400/41
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/401/41
METASTASES TO BONENeoplasms benign, malignant and unspecified (incl cysts and polyps)1/400/41
METASTASES TO LIVERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/400/41
METASTASES TO LUNGNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/400/41
Most frequent other events
Showing 10 of 39
Most frequent other events
EventLetrozoleLetrozole + Zolendronic Acid
ARTHRALGIAMusculoskeletal and connective tissue disorders11/4014/41
BONE PAINMusculoskeletal and connective tissue disorders12/4014/41
FATIGUEGeneral disorders2/4012/41
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders5/4010/41
HOT FLUSHVascular disorders9/409/41
PYREXIAGeneral disorders0/409/41
HEADACHENervous system disorders5/409/41
NAUSEAGastrointestinal disorders0/407/41
CHILLSGeneral disorders1/407/41
ALOPECIASkin and subcutaneous tissue disorders6/406/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LetrozoleLetrozole + Zoledronic AcidTotal
<=18 years000
Between 18 and 65 years373976
>=65 years000
Age Continuous
Age Continuous(years)LetrozoleLetrozole + Zoledronic AcidTotal
Mean61.3 ± 7.358.4 ± 7.359.8 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)LetrozoleLetrozole + Zoledronic AcidTotal
Female373976
Male000
08

Study locations

23 sites
  • Novartis Investigative Site
    Deggendorf, Germany
  • Novartis Investigative Site
    Frankfurt/Main, Germany
  • Novartis Investigative Site
    Freiburg, Germany
  • Novartis Investigative Site
    Georgsmarienhutte, Germany
  • Novartis Investigative Site
    Gottingen, Germany
  • Novartis Investigative Site
    Halle, Germany
  • Novaertis Investigative Site
    Hamein, Germany
  • Novartis Investigative Site
    Hannover, Germany
  • Novartis Investigative Site
    Hoxter, Germany
  • Novartis Investigative Site
    Ilsede, Germany
  • Novartis Investigative Site
    Jena, Germany
  • Novartis Investigative Site
    Karlsruhe, Germany
  • Novartis Investigative Site
    Koln, Germany
  • Novartis Investigative Site
    Leer, Germany
  • Novartis Investigative Site
    Lubeck, Germany
  • Novartis Investigative Site
    Mannheim, Germany
  • Novartis Investigative Site
    Munster, Germany
  • Novartis Investigative Site
    Rostock, Germany
  • Novartis Investigative Site
    Salzgitter, Germany
  • Novartis Investigative Site
    Schwenningen, Germany
  • Novartis Investigative Site
    Stendal, Germany
  • Novartis Investigative Site
    Volklingen, Germany
  • Novartis Investigative Site
    Witten, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2006
First posted
Jun 2, 2006
Start
Jan 2006
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Nov 16, 2011
Last update
Nov 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00332709
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jun 2, 2006
Start date
Jan 2006
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Nov 16, 2011
Last update
Nov 16, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion